PTC Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
PTC Therapeutics, Inc. (PTCT) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $24.42 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-08
- PTC Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $24.42M, a 10.40% increase year-over-year.
- PTC Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $38.24M.
- PTC Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $21.00M, a 25.76% increase year-over-year.
- PTC Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-03-31 was $22.12M, a 7.33% increase year-over-year.
- PTC Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$20.81M.
- PTC Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$145.17M.
- PTC Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$127.83M.
- PTC Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2012 was -$189.00K, a 100.68% decline from fiscal 2011.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2017-03-31 | $24.42M 10-Q · filed 2017-05-08 | ||||||
| 2016-09-30 | $38.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $59.23M derived: sum of 2 quarters · filed 2016-11-03 | $81.35M 10-Q · filed 2016-11-03 | $29.52M derived: sum of 4 quarters · filed 2017-05-08 | |||
| 2016-06-30 | $21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $43.11M 10-Q · filed 2016-08-04 | -$8.72M derived: sum of 3 quarters · filed 2017-05-08 | -$15.00M derived: sum of 4 quarters · filed 2017-05-08 | |||
| 2016-03-31 | $22.12M 10-Q · filed 2017-05-08 | -$29.71M derived: sum of 2 quarters · filed 2017-05-08 | -$36.00M derived: sum of 3 quarters · filed 2017-05-08 | -$19.30M derived: sum of 4 quarters · filed 2017-05-08 | |||
| 2015-12-31 | -$51.83M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$58.11M derived: sum of 2 quarters · filed 2016-11-03 | -$41.42M derived: sum of 3 quarters · filed 2016-11-03 | -$20.81M 10-K · filed 2016-02-29 | |||
| 2015-09-30 | -$6.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $10.41M derived: sum of 2 quarters · filed 2016-11-03 | $31.02M 10-Q · filed 2016-11-03 | -$82.17M derived: sum of 4 quarters · filed 2016-11-03 | |||
| 2015-06-30 | $16.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $37.30M 10-Q · filed 2016-08-04 | -$75.88M derived: sum of 3 quarters · filed 2016-08-04 | -$27.50M derived: sum of 4 quarters · filed 2016-08-04 | |||
| 2015-03-31 | $20.61M 10-Q · filed 2016-05-05 | -$92.58M derived: sum of 2 quarters · filed 2016-05-05 | -$44.20M derived: sum of 3 quarters · filed 2016-05-05 | -$120.29M derived: sum of 4 quarters · filed 2016-05-05 | |||
| 2014-12-31 | -$113.19M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$64.81M derived: sum of 2 quarters · filed 2016-02-29 | -$140.90M derived: sum of 3 quarters · filed 2016-02-29 | -$145.17M 10-K · filed 2016-02-29 | |||
| 2014-09-30 | $48.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$27.72M derived: sum of 2 quarters · filed 2015-11-09 | -$31.98M 10-Q · filed 2015-11-09 | -$26.11M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | -$76.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$80.36M 10-Q · filed 2015-07-31 | -$74.49M derived: sum of 3 quarters · filed 2016-02-29 | -$196.51M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | -$4.27M 10-Q · filed 2015-05-05 | $1.60M derived: sum of 2 quarters · filed 2016-02-29 | -$120.42M derived: sum of 3 quarters · filed 2016-02-29 | -$132.07M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$116.15M derived: sum of 2 quarters · filed 2016-02-29 | -$127.81M derived: sum of 3 quarters · filed 2016-02-29 | -$127.83M 10-K · filed 2016-02-29 | -$127.83M 10-K · filed 2014-03-06 | ||
| 2013-09-30 | -$122.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$133.68M derived: sum of 2 quarters · filed 2014-11-06 | -$133.70M 10-Q · filed 2014-11-06 | -$133.70M 10-Q · filed 2013-11-14 | -$133.70M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | -$11.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$11.68M 10-Q · filed 2014-08-07 | -$11.68M 10-Q · filed 2013-08-13 | -$11.69M derived: sum of 3 quarters · filed 2015-03-02 | -$11.69M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | -$21.00K 10-Q · filed 2014-05-06 | -$26.49K derived: sum of 2 quarters · filed 2015-03-02 | -$30.78K derived: sum of 3 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | -$5.49K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$9.78K derived: sum of 2 quarters · filed 2015-03-02 | -$189.00K 10-K · filed 2015-03-02 | -$188.68K 10-K · filed 2014-03-06 | |||
| 2012-09-30 | -$4.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | -$183.51K 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | -$179.22K 10-Q · filed 2013-08-13 | ||||||
| 2011-12-31 | $27.70M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |